# Therapeutic peptides

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Guide
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/therapeutic-peptides.html

> Peptides are short amino-acid chains (2-50 residues) sitting between small molecules and biologics: highly target-specific, cheap to synthesize, but mostly not orally bioavailable. The evidence is bimodal: GLP-1 agonists are approved drugs with huge phase 3 programs and elamipretide won accelerated FDA approval for Barth syndrome in 2025, while BPC-157, TB-500 and the Russian bioregulators rest on animal data or Russian clinical literature. The dominant practical risk is sourcing, because research peptides have no standardized quality control.

> Comprehensive guide to therapeutic peptides — the fastest-expanding therapeutic frontier in regenerative medicine, cognitive enhancement, metabolic optimization, and anti-aging. Peptides offer mechanisms unavailable to small molecules or biologics: target specificity, favorable safety profiles, and gene-level regulation.  
  
This section covers the complete therapeutic peptide landscape — from Russian bioregulators (Khavinson's 50-year program) to cutting-edge wound-healing compounds (BPC-157) to cognitive peptides (Semax, Selank) and metabolic regulators (MOTS-C, GLP-1 analogs).

## Why Peptides Are Different

### Advantages Over Traditional Therapeutics

Property | Small Molecules | Biologics | Peptides  
---|---|---|---  
**Target specificity** | Low-moderate | High | Very high  
**Oral bioavailability** | Yes | Poor | Limited (some notable exceptions)  
**Manufacturing cost** | Low | Very high | Moderate  
**Immunogenicity** | Low | Moderate-high | Low  
**Tissue penetration** | Good | Poor | Moderate  
**Molecular weight** | <500 Da | >5000 Da | 500-5000 Da  
**Synthesis complexity** | Simple | Complex | Moderate  
  
### The Peptide Advantage in Practice

The peptide category occupies a unique pharmacological niche:

  * **More specific than small molecules** — Can target exact receptor subtypes
  * **Easier to manufacture than biologics** — Chemical synthesis, not recombinant
  * **Better tissue penetration than biologics** — Can cross membranes (some)
  * **Gene-level effects** — Russian bioregulators directly modify gene expression



### Peptide Categories by Origin

Source | Examples | Key Characteristic  
---|---|---  
**Endogenous human** | Insulin, oxytocin, ACTH | Identical to human sequences; best safety  
**Synthesized/modified** | BPC-157, TB-500, Epitalon | Engineered for stability, potency, bioavailability  
**Animal-derived** | GHK-Cu (from albumin), thymosin | Extracted; complex multi-target mechanisms  
**Russian/Soviet-developed** | Epitalon, Semax, Selank, Thymalin | Extensive Russian clinical use; unique mechanisms  
  
## Quick Reference: Evidence Levels by Peptide

Peptide | Evidence Level | FDA Status | Primary Mechanism | Risk  
---|---|---|---|---  
**BPC-157** | Animal studies (extensive) | Not approved | FAK-ERK signaling; angiogenesis | Low  
**TB-500** | Animal studies (strong) | Not approved | Actin regulation; cell migration | Low  
**GHK-Cu** | Human studies (moderate) | Not approved | Gene modulation (4000+ genes) | Low  
**SS-31** | Phase 1-3 + approval | ✅ FDA approved (Barth syndrome) | Cardiolipin binding | Low  
**MOTS-C** | Preclinical + early human | Not approved | AMPK activation | Low  
**Epitalon** | Russian clinical trials | Not approved (Russia: approved) | Telomerase activation | Low  
**Thymalin** | Russian clinical trials | ✅ Russian approved | Immune modulation | Low  
**Semax** | Russian clinical trials | ✅ Russian approved | BDNF upregulation | Low  
**Selank** | Russian clinical trials | ✅ Russian approved | GABA modulation | Low  
**Dihexa** | Animal only | Not approved | HGF/c-Met | ⚠️ Cancer concern  
**GLP-1 (Semaglutide)** | Multiple RCTs | ✅ FDA approved | GLP-1 receptor agonist | Moderate  
  
## Administration Routes Reference

Route | Peptides | Pros | Cons  
---|---|---|---  
**Subcutaneous (SC)** | Most peptides (BPC-157, TB-500, Epitalon, Thymalin) | Standard systemic delivery; predictable absorption | Requires injection  
**Intramuscular (IM)** | TB-500 (sometimes) | Good for local tissue targeting | Less common  
**Intranasal/Spray** | Semax, Selank | Bypasses first-pass metabolism; convenient | Some peptides not bioavailable nasally  
**Oral** | BPC-157 (unique stability) | Most convenient | Most peptides destroyed in GI tract  
**Topical** | GHK-Cu | Local effect; skin applications | Limited systemic effect  
**Sublingual** | Some peptides | Bypasses GI and first-pass | Variable absorption  
  
## Quality and Sourcing (Critical)

### The #1 Risk in Peptide Therapy

**Supplier quality varies enormously.** Unlike FDA-approved pharmaceuticals, research peptides and compounded peptides have no standardized quality control. This is the single greatest risk factor in peptide therapy.

### What to Demand From Any Supplier

Requirement | Why | How to Verify  
---|---|---  
**≥98% purity (HPLC)** | Impurities can be harmful | CoA with HPLC data  
**Mass spectrometry** | Confirms exact sequence | MS report on request  
**Endotoxin testing** | Required for injectables | LAL test or equivalent  
**Lyophilized (freeze-dried)** | Stability during shipping/storage | Visual: powder, not liquid  
**Cold chain** | Temperature-sensitive | Packaging with cold packs  
**ISO/IEC 17025 lab** | Accredited third-party testing | Accreditation number  
  
### Red Flags

Red Flag | What It Signals  
---|---  
No CoA available | Cannot verify purity  
Price too low (e.g., $20/vial) | Likely impure or counterfeit  
"Research use only" with no testing | Marketing, not quality  
Wrong sequence claimed | Supplier doesn't verify  
Liquid form (unpreserved) | Degradation risk  
No refrigeration required | Stability concerns  
  
### Trusted Source Categories

Source Type | Examples | Notes  
---|---|---  
**US compounding pharmacies** | Lowest risk; requires prescription | Best for patient safety  
**Reputable research suppliers** | Multiple with GMP; CoA required | For experienced users  
**Russian pharmaceutical** | Khavinson-origin products | Best for bioregulators specifically  
  
## Recommended Reading Order

### For Newcomers to Peptides

  1. **Foundation** → [Overview - Therapeutic Peptides](therapeutic-peptides.html) — Categories, evidence levels, regulatory status
  2. **Safety first** → [Peptide Sources and Quality](peptide-sources-and-quality.html) — How to verify any peptide product
  3. **Protocols** → [Peptide Protocols and Dosing](therapeutic-peptides.html) — General administration guidelines
  4. ****→[BPC-157 (Body Protection Compound)](bpc-157-body-protection-compound.html) — Best-studied; oral option



### For Specific Applications

Goal | Start Here | Additional Files  
---|---|---  
Wound/tissue healing | [BPC-157 (Body Protection Compound)](bpc-157-body-protection-compound.html) | [Peptide Therapy for Injuries](peptide-therapy-for-injuries.html)  
Cognitive enhancement | [Semax](semax-acth4-7-pgp-neurotrophic-peptide.html) | [Selank](selank-tuftsin-derived-anxiolytic-peptide.html)  
Anti-aging/longevity | [Epitalon](epitalon-aedg-tetrapeptide-telomerase-pineal-axis-and-geroprotective-evidence.html) | [Thymalin](thymalin.html), Khavinson Peptides  
Metabolic/weight | GLP-1 Peptides... | [Metabolic Health and Insulin](metabolic-health-and-insulin.html)  
Immune support | [Thymalin](thymalin.html) | [Immune Function](immune-function.html)  
Mitochondrial | [MOTS-C](mots-c-mitochondrial-open-reading-frame-of-12s-rrna-type-c.html) | [Mitochondrial Health](mitochondrial-health.html)  
  
## Practical Notes

### Uses

  1. **Verify quality** — Get CoA from supplier before use
  2. ****— Test tolerance with lowest dose first
  3. **Track everything** — Baseline symptoms, dose, timing, effects, side effects
  4. **Consider oral BPC-157 first** — Safest entry point; meaningful evidence



### Common Mistakes

Mistake | Why It Matters  
---|---  
Buying cheapest peptides | Purity is everything; impurities are dangerous  
No cycling | Receptor downregulation; reduced efficacy  
Stacking too many at once | Can't identify what works  
Ignoring source quality | Supplier verification is non-negotiable  
Assuming "natural" = safe | Peptides are biologically active; respect potency  
  
## Notes

### Regulatory Status by Peptide

Peptide | US Status | Russian Status | Notes  
---|---|---|---  
BPC-157 | Research only | Not approved | Most studied; not approved anywhere  
TB-500 | Research only | Not approved | Thymosin Beta-4 analog  
GHK-Cu | Cosmetic use | Not approved | Used in skin care products  
SS-31 | FDA approved | Not approved | Barth syndrome only  
MOTS-C | Research only | Not approved | Investigational  
Epitalon | Research only | Approved | Russian clinical use  
Thymalin | Not approved | Approved | Russian clinical use  
Semax | Not approved | Approved | Russian clinical use  
Selank | Not approved | Approved | Russian clinical use  
GLP-1 (Semaglutide) | FDA approved | Approved | Mainstream pharmaceutical  
  
### Future Developments to Watch

  * **SS-31** (Elamipretide): Phase 3 trials for dry age-related macular degeneration (another indication)
  * **BPC-157** : Growing number of compassionate use cases; no formal clinical trials yet
  * **Epitalon** : Western research interest increasing; telomerase mechanism attracting attention
  * **MOTS-C** : Phase 1 trials underway for metabolic indication



**2026 Regulatory Alert (UPDATED 2026-08-19):** At the July 23–24, 2026 PCAC meeting, the committee recommended **6 of 7 peptides** for the 503A Bulks List: BPC-157 (8–6), KPV (8–6), TB-500, MOTS-c, Epitalon (7–5), Semax (8–5) — all over FDA career-staff objections (characterization, impurities, immunogenicity, insufficient efficacy data). **Emideltide/DSIP was rejected (6–7).** Votes are non-binding; FDA's final listing decision was still pending as of mid-Aug 2026. Five more peptides (incl. GHK-Cu, LL-37, Dihexa) go to PCAC before Feb 2027. Full analysis: [FDA Peptide Reclassification 2026 — Regulatory Intelligence](fda-peptide-reclassification-2026.html). Current sourcing status unchanged until final rule: largely research/gray market; EU/EMA significantly stricter. Monitor FDA compounding lists before sourcing. See [Peptide Sources and Quality](peptide-sources-and-quality.html).

## Doses in studies

### Overview

  * **Have strict storage requirements** (refrigeration, protection from light)
  * **Are almost always administered subcutaneously** or intramuscularly (IM)



> **⚠️ Disclaimer:** These are research protocols. Most peptides discussed here are not FDA-approved. Consult a qualified practitioner.

* * *

### Required Materials

Material | Purpose | Notes  
---|---|---  
**Sterile Sodium Chloride (0.9% NaCl)** | Alternative solvent | Single-use; no preservative  
  
### reconstitution Math

**Key formula:**
    
    
    Concentration (mcg/mL) = Total peptide (mcg) ÷ Volume of water (mL)
    
    Dose (mcg) = Concentration (mcg/mL) × Volume to inject (mL)
    

**Common example:**

> **Dosing example for BPC-157:**

Vial Size | Water Added | Concentration  
---|---|---  
5mg | 1mL | 5000 mcg/mL  
5mg | 2mL | 2500 mcg/mL  
10mg | 2mL | 5000 mcg/mL  
  
* * *

### Subcutaneous

**Most common route for therapeutic peptides.**

**Advantages:** \- Slow absorption → sustained release effect \- Easy self-administration \- Minimal pain \- Good bioavailability

### Intramuscular (IM)

**Used for certain peptides (e.g., some growth hormone-releasing peptides).**

### Oral Administration

**Limited to specific peptides with oral bioavailability:**

  * **BPC-157** : Stable in gastric juice; documented oral bioavailability
  * **Selank** : Developed as nasal/oral formulation
  * **Semax** : Originally developed as nasal formulation



> **Note:** Most therapeutic peptides are NOT orally bioavailable due to degradation in the gastrointestinal tract.

### Nasal Administration

**Used for peptides targeting CNS effects:**

  * **Semax/Semax nasal**
  * **Selank**
  * **DIhexa** (experimental)



**Procedure:** \- Use dedicated nasal spray bottles \- Tilt head back slightly \- Spray into nostril \- Avoid sniffing (pulls medication to stomach)

* * *

### TB-500 (Thymosin Beta-4)

> **Notes:** \- Often combined with BPC-157 in "BP-500" blend \- Not FDA-approved; no established human dose

### Thymosin Alpha-1 (Immunomodulator)

> **Clinical data:** Thymosin Alpha-1 has FDA approval (as Zadaxin) in 35+ countries for: \- Chronic hepatitis B and C \- HIV/AIDS \- Certain cancers (as adjuvant therapy) \- COVID-19 (investigational)

**Source:** PMID [32448923](https://pubmed.ncbi.nlm.nih.gov/32448923/), PMID [10821397](https://pubmed.ncbi.nlm.nih.gov/10821397/)

### Thymalin (Thymus Extract Peptide)

> **Source:** Russian clinical practice; limited Western data. See [Thymalin](thymalin.html) for details.

### GLP-1 Agonists (Semaglutide, Tirzepatide)

Peptide | Escalation | Maintenance  
---|---|---  
Semaglutide (Ozempic) | Every 4 weeks | —  
Semaglutide (Wegovy) | Every 4 weeks | —  
Tirzepatide (Mounjaro) | Every 4 weeks | —  
  
> **Note:** GLP-1 peptides are FDA-approved pharmaceuticals with established dosing protocols. See [GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide)](glp-1-peptides-semaglutide-tirzepatide-retatrutide.html) for detailed information.

* * *

### Approaches Reported in the Literature

Peptide Type | Notes  
---|---  
BPC-157 | Generally safe to use continuously  
TB-500 | Growth promotion plateaus  
Thymosin Alpha-1 | Immune system assessment  
GH secretagogues | IGF-1 normalization  
GHRP-2/GHRP-6 | Receptor desensitization  
  
### Uses

Some peptides are used in "pulsing" fashion — high-dose administration once weekly rather than daily:

Peptide | Application  
---|---  
TB-500 | Maintenance therapy  
BPC-157 | Systemic support  
  
* * *

### Side Effects by Category

Category | Common Side Effects | Notes  
---|---|---  
**Immune-stimulating** | Flu-like symptoms | Thymosin family; usually mild  
**GH/IGF-1 affecting** | Water retention, numbness | Monitor; dose-dependent  
**Gastrointestinal** | Nausea, diarrhea | Especially GLP-1 agonists  
  
### Contraindications

> **Relative contraindications:** \- Pregnancy/breastfeeding (insufficient data) \- Active cancer (some peptides may affect growth) \- Autoimmune conditions (immune-modulating peptides) \- Organ transplantation (immunosuppression concerns)

### Drug Interactions

Interaction | Effect | Recommendation  
---|---|---  
Immunosuppressants | Countereffects | Avoid or adjust  
Anticoagulants | Bleeding risk (wound healing peptides) | Monitor closely  
NSAIDs | Additive GI effects (BPC-157 may be protective) | Usually compatible  
Growth hormone | Additive effects | Avoid or monitor IGF-1  
  
* * *

### Quality and Sourcing

> **Critical:** Peptide quality varies dramatically by source. See [Peptide Sources and Quality](peptide-sources-and-quality.html) for detailed guidance.

### Red Flags

⚠️ **Warning signs of poor quality:** \- Price too low to be plausible \- No certificate of analysis (COA) \- No third-party testing \- Unverifiable manufacturer \- Inconsistent appearance between orders \- Claims that seem too good to be true

### Quality Markers

✅ **What to look for:** \- Third-party lab testing \- COA available on request \- GMP-certified manufacturer \- Proper packaging (glass vial, not plastic) \- Adequate cold chain \- Batch numbers traceable

* * *

### Storage Guidelines

Form | Storage | Duration | Notes  
---|---|---|---  
Lyophilized powder | 2-8°C (refrigerated) | 2-3 years | Protect from moisture  
Lyophilized powder | -20°C (frozen) | Extended | Best for long-term  
  
### Stability Factors

  * **Light:** Protect from UV exposure
  * **Time:** Discard after stability window



* * *

## Sources

1. PubMed 25940644 (PubMed 25940644)
2. PubMed 31692455 (PubMed 31692455)
3. PubMed 27824938 (PubMed 27824938)
4. PubMed 28753712 (PubMed 28753712)
5. PubMed 29406255 (PubMed 29406255)
6. PubMed 32040947 (PubMed 32040947)
7. PubMed 32448923 (PubMed 32448923)
8. PubMed 10821397 (PubMed 10821397)